iCAD (ICAD)
Oppenheimer analyst Francois Brisebois assigned a Buy rating to iCAD today and set a price target of $28.00. The company’s shares closed last Wednesday at $17.73.
According to TipRanks.com, Brisebois is a 3-star analyst with an average return of 10.2% and a 45.2% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Avadel Pharmaceuticals, Diamedica Therapeutics, and Kala Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for iCAD with a $23.43 average price target, representing a 29.3% upside. In a report issued on April 22, Guggenheim also initiated coverage with a Buy rating on the stock with a $24.00 price target.